Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.

Perspective Therapeutics, Inc.

Perspective Therapeutics is a pharmaceutical company focused on developing therapies for treating cancer from the inside out. The company aims to create treatments that make a difference for cancer patients and the clinicians who treat them.

Perspective Therapeutics

We develop game-changing therapies that make an impactful difference for cancer patients and the clinicians who treat them.

Our first human imaging with [203Pb]PSV359 suggests rapid uptake and sustained retention in multiple cancer types. PSV359 is a novel peptide developed by our in-house discovery team which targets Fibroblast Activation Protein-α (FAP).  

Imaging was performed by Dr. Ishita Sen’s group at Fortis Memorial Research Institute - India.

Further information will be available in upcoming presentations and publications.
 
https://lnkd.in/ePh7Z6Zh

#nuclearmedicine #radiopharma #oncology

We're #hiring a new Discovery Lab Organic Chemist in Coralville, Iowa. Apply today or share this post with your network.

Perspective Therapeutics is pleased to announce the appointment of Steve Keefe, MD, MSCE, as Senior Vice President, Clinical Development. 

Dr. Keefe joins us from Merck, where he led global clinical development in gynecologic cancers. His team at Merck was instrumental in advancing groundbreaking therapies, including pembrolizumab, olaparib, and lenvatinib, as well as pioneering combination strategies with earlier-stage compounds.

He received his MD from the University of Chicago and completed a fellowship in Medical Oncology at Penn Medicine. His journey in oncology continued as a clinical investigator at the University of Pennsylvania, where he served on the faculty of the School of Medicine.

We are confident that Dr. Keefe's broad experience in oncology drug development further strengthens our capabilities in bringing our novel radiopharmaceutical medicines all the way to patients and their families. Join us in welcoming Dr. Keefe to the team!

#Radiopharmaceuticals #Oncology

We're excited to be attending the 3rd Annual Targeted Radiopharmaceuticals Summit this week!
Our CBO, Amos Hedt, will be participating in a panel discussion on Wednesday, July 31, and a seminar on Thursday, August 1, focused on the current state and the future of #radiopharmaceuticals.

Learn more at: https://bit.ly/3WrwrcX

Perspective’s CB7-Adma Pre-targeting Platform!

Host -> CB7-conjugated antibody
Guest -> Adma-modified radionuclide
Lag time post Host administration -> Flexible (determined by peak Host tumor uptake and clearance) 

Our best-in-class platform aims to transform a wide range of existing molecules and targets into “radio-ADCs” to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. Revolutionizing cancer treatment with a new breakthrough approach.

https://lnkd.in/eBr3zAT6

We're #hiring a new Executive Administrative Assistant in Coralville, Iowa. Apply today or share this post with your network.

COM:PERSPECTIVETHERAPEUTICS

Perspective Therapeutics

Last Close

3.00

22/11 21:00

Market Cap

234.53M

Beta: -

Volume Today

9.18M

Avg: -